fentanyl pfizer transdermal patch 005mg h - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

fenpatch 50 fentanyl 50 mcg/hr transdermal patch pouch

medis pharma pty ltd - fentanyl, quantity: 8.25 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

fenpatch 25 fentanyl 25 mcg/hr transdermal patch pouch

medis pharma pty ltd - fentanyl, quantity: 4.125 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; titanium dioxide; polypropylene; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

fenpatch 12 fentanyl 12 mcg/hr transdermal patch pouch

medis pharma pty ltd - fentanyl, quantity: 2.063 mg - drug delivery system, transdermal - excipient ingredients: polypropylene; polyethylene terephthalate; titanium dioxide; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.